Home >Research Technology Management>Technology for Licensing
Anti-infective compounds (Tuberculosis)
US Provisional application 62/015,056.
Kevin Pethe, Sunhee Kang
Stage of Development
Summary of Invention
The invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
Tuberculosis (TB) is one of the most widespread disease in the world, killing approximately 1 million every year. Current therapeutic drugs for TB takes long to cure and can be toxic. There is no cure for resistant TB. The new therapeutic drugs for multi-resistant TB will save millions of lives and bring revenue of 400 billion won every year. These compounds are the novel drug candidates to treat TB.